Intersolar Europe: How About Some More?
The German government’s goal is to have an equal share of large-scale power plants and roof-mounted systems. In 2023, the large-scale ground-mounted segment was able to increase by 45 percent. With the adoption of Solar Package I, this segment will continue to grow. The package of measures aims to reduce the red tape associated with solar deployment in order to achieve an annual growth of 22 gigawatt peak from 2026. The latest applications, products and business models for large-scale PV power plants will be on display at Intersolar Europe, the world’s leading exhibition for the solar industry. It will be held in Munich from June 19–21 as part of The smarter E Europe, the continent’s largest alliance of exhibitions for the energy industry. Some 3,000 exhibitors and over 115,000 visitors from all corners of the globe are expected to attend. The event will take place across 19 exhibition halls and an Outdoor Area.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529516051/en/
Intersolar Europe presents innovations in the field of hybrid systems. (© Solar Promotion GmbH)
Hybrid power plants consisting of PV and wind power or storage, or both, offer various benefits: Sun and wind complement each other’s generation profiles and can be combined in a system, making optimal use of energy infrastructure such as interconnection points and the space required to implement the system. The combination with energy storage comes with additional advantages: It can smooth out the volatility of renewables, and the stored electricity can be fed into the grid when it is needed – or it can be traded for a profit. Energy arbitrage enables the targeted provision and marketing of solar and wind energy on the energy exchange. The electricity is stored when the price is low or a lot of renewable electricity is being produced. When it is profitable to sell the stored electricity, it is fed into the grid.
The latest technologies in operation and maintenance
Artificial intelligence (AI) is all the rage right now. It is also increasingly being used in the solar industry, especially in operations and maintenance (O&M). The AI-driven detection and analysis of incidents and deviations in operations and the standardized creation and selection of tickets are processes in which AI can be used to quickly process large amounts of data. In O&M, AI helps free up human resources for more complex tasks and standardize operations. What’s more, AI-supported software solutions can process weather data and create generation forecasts.
Special solar systems: parking lot PV, agricultural PV and floating PV
With Solar Package I, the “special solar systems” defined in the German Renewable Energy Sources Act EEG now have their own tender segment. These applications are becoming more prevalent and dual land use concepts are coming to the forefront of solar deployment plans. The maximum value for tenders has been raised to 9.5 cents/kWh. The products in this segment are rapidly evolving: carport substructures, elevated vertical and horizontal solar technology with and without trackers for agricultural PV, and mounting solutions for floating PV.
Intersolar Europe
As the world’s leading exhibition for the solar industry, Intersolar Europe demonstrates the enormous vitality of the solar market. For more than 30 years, it has been providing a networking opportunity for key players, focusing on the latest trends, developments and business models under the motto “Connecting Solar Business”. Intersolar Europe will take place from June 19–21, 2024 as part of The smarter E Europe at Messe München.
For more information, please visit: www.intersolar.de.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529516051/en/
Contact information
Roberto Freiberger
ressourcenmangel an der Panke GmbH
Schlesische Straße 26/c4
10997 Berlin
roberto.freiberger@ressourcenmangel.de
Peggy Zilay
Solar Promotion GmbH
P.O. Box 100 170
75101 Pforzheim
zilay@solarpromotion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of Xella to Holcim20.10.2025 07:40:00 EEST | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund X, LP of a binding agreement to sell Xella Group (“Xella”), a leading provider of walling solutions, to Holcim, the leading partner for sustainable construction. The transaction values Xella at approximately €1.85 billion. Headquartered in Duisburg, Germany, Xella is a European provider of efficient and sustainable walling solutions for the entire house shell, operating brands such as Ytong, Silka, Hebel and Multipor. The company employs more than 4,000 team members. In partnership with Lone Star, Xella has taken significant strides in recent years to optimize its offering by strategically focusing the business on walling solutions, while also enhancing its commercial and digital capabilities. Under Lone Star’s stewardship, Xella has also continued to progress its sustainability initiatives. Today, the business stands as a market leader in its sector with a strong reputation for a people-first c
Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products20.10.2025 07:00:00 EEST | Press release
Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the market introduction of several additions to its MOSS!MODULARITY™ platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019799867/en/ MOSS!MODULARITY Injection Screw MOSS!MODULARITY encompasses a broad range of products and technologies for spinal surgery based around the concept of providing an advanced modular workflow for posterior stabilization and deformity correction. The modular workflow allows surgeons to place the headless bone screw shafts as a first step, without the tulip heads attached, and offers several advantages over working with traditional pre-assembled pedicle screws, e.g.: Improved visualisation and access to the surgical working space; Precise decompression, decortication and osteotomies without any interference with polyaxial tulip heads; Increased surgic
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom